

Supplemental Table 1

Type of immunosuppression	Active TB (%)	95% CI	N total/TST+ only	TST+ prevalence (%)	TB disease (N)	Data adjusted for:		Observation period
						IPT <sup>a</sup>	Strain clustering	
<b>antiTNF (infliximab)</b>								
US <sup>1</sup>	0.7	0.2-1.8	6460/594	9	4	no	no	1-3 years
US <sup>2</sup>	0.6	0.4-0.9	121,000/2,833	4.2 <sup>b</sup>	17 <sup>c</sup>	no	no	2 years
France <sup>3</sup>	1.0 <sup>d</sup>	0.6-1.8	unknown/1154 <sup>e</sup>	22 <sup>f</sup>	12 <sup>d</sup>	no	no	2-5 years
Spain <sup>4</sup>	4.9	3 to 7.8	1540/347 <sup>e</sup>	22 <sup>g</sup>	17	no	no	1.1 years
<b>SOT</b>								
Turkey kidney <sup>5</sup>	11.3	7.4-17	443/177 <sup>e</sup>	40 <sup>h</sup>	20	no	no	15 months for 1 grp, 55 months for 2 <sup>nd</sup> grp
US kidney <sup>6</sup>	9.9	7.9-12.4	15,870/666 <sup>e</sup>	4.2 <sup>b</sup>	66	no	no	1.6 years
Spain multiple organs <sup>7</sup>	4.4	2.9-6.8	4388/471	19	21	yes	no	1 year
<b>HIV/AIDS (US)</b>								
US <sup>8</sup>	2.9	0.0-15.8	/35	100 <sup>i</sup>	1 <sup>j</sup>	no	yes	5 years
US <sup>9</sup>	11.3	6.5-19.0	466/106	25	12	yes	yes	5 years
<b>HSCT</b>								
Taiwan <sup>10</sup>	8.0	5.8-10.7	2040/492 <sup>e</sup>	24 <sup>k</sup>	39	no	no	10 years
US <sup>11</sup>	0	0.0-14.0	29/29	100 <sup>i</sup>	0	Yes (none treated)	no	5 years
Korea <sup>12</sup>	10.3	6.4-16.2	550/155 <sup>e</sup>	28 <sup>l</sup>	16	no (none treated)	no	5.8 years
India <sup>13</sup>	7.1	2.8-16.1	175/70 <sup>e</sup>	40 <sup>m</sup>	5	no (none treated)	no	3.1 years

#### Footnotes

a, INH preventive therapy; b, estimated TST positive prevalence based on US average in 1999-2000<sup>14</sup>; c, US patients only, as this was the population for which TB disease rates were determined; d, only patients from 2000 are included because after that INH preventive therapy was given to some or most TST-positive patients; e, estimated number of tuberculin skin test (TST)-positive persons based on number of those with TB and on the % of TST-positive people with active TB; f, estimated TST positive prevalence based on a 2005-2009 French study<sup>15</sup> of patients with chronic inflammatory arthritis who were candidates for biologic therapy, where the T-spot positive prevalence were taken as the more specific figure; g, TST prevalence in a later study of Spanish patients with rheumatologic diseases undergoing skin testing prior to infliximab therapy<sup>16</sup>; h, IGRA-positive prevalence in a study of Turkish patients undergoing testing prior to biologic therapy for inflammatory bowel disease<sup>17</sup>; i, only TST-positive patients were studied; j, of 6 patients with TB, five were clustered, indicating recent infection, not activation of remote TB infection; k, TST+ prevalence is based on the IGRA-positive prevalence of Taiwanese persons<sup>18</sup>; l, IGRA-positive prevalence of HSCT patients in same hospital a few years later<sup>12</sup>; m, TB infection prevalence cited in paper regarding the Indian population, not specifically the study group

## References

1. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. *Arthritis Rheum* 2004;50:372-9.
2. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. *N Engl J Med* 2001;345:1098-104.
3. Baldin B, Dozol A, Spreux A, Chichmanian RM. Tuberculoses lors de traitements par l'infliximab. Suivi national du 1er janvier 2000 au 30 juin 2003. *Presse Med* 2005;34:353-7.
4. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD, Group B. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. *Arthritis Rheum* 2003;48:2122-7.
5. Atasever A, Bacakoglu F, Toz H, et al. Tuberculosis in renal transplant recipients on various immunosuppressive regimens. *Nephrol Dial Transplant* 2005;20:797-802.
6. Klote MM, Agodoa LY, Abbott K. Mycobacterium tuberculosis infection incidence in hospitalized renal transplant patients in the United States, 1998-2000. *Am J Transplant* 2004;4:1523-8.
7. Torre-Cisneros J, Doblaz A, Aguado JM, et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. *Clin Infect Dis* 2009;48:1657-65.
8. Moss AR, Hahn JA, Tulsy JP, Daley CL, Small PM, Hopewell PC. Tuberculosis in the homeless. A prospective study. *Am J Respir Crit Care Med* 2000;162:460-4.
9. Horsburgh CR, Jr., O'Donnell M, Chamblee S, et al. Revisiting rates of reactivation tuberculosis: a population-based approach. *Am J Respir Crit Care Med* 2010;182:420-5.
10. Fan WC, Liu CJ, Hong YC, et al. Long-term risk of tuberculosis in haematopoietic stem cell transplant recipients: a 10-year nationwide study. *Int J Tuberc Lung Dis* 2015;19:58-64.
11. Cheng MP, Kusztoz AE, Bold TD, et al. Risk of Latent Tuberculosis Reactivation after Hematopoietic-Cell Transplantation. *Clin Infect Dis* 2019;in press.
12. Lee HJ, Lee DG, Choi SM, et al. The demanding attention of tuberculosis in allogeneic hematopoietic stem cell transplantation recipients: High incidence compared with general population. *PLoS One* 2017;12:e0173250.
13. Agrawal N, Aggarwal M, Kapoor J, et al. Incidence and clinical profile of tuberculosis after allogeneic stem cell transplantation. *Transpl Infect Dis* 2018;20:e12794.
14. Bennett DE, Courval JM, Onorato I, et al. Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000. *Am J Respir Crit Care Med* 2008;177:348-55.

15. Costantino F, de Carvalho Bittencourt M, Rat AC, et al. Screening for latent tuberculosis infection in patients with chronic inflammatory arthritis: discrepancies between tuberculin skin test and interferon-gamma release assay results. *J Rheumatol* 2013;40:1986-93.
16. Gomez-Reino JJ, Carmona L, Angel Descalzo M, Biobadaser G. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. *Arthritis Rheum* 2007;57:756-61.
17. Cekic C, Aslan F, Vatansever S, et al. Latent tuberculosis screening tests and active tuberculosis infection rates in Turkish inflammatory bowel disease patients under anti-tumor necrosis factor therapy. *Ann Gastroenterol* 2015;28:241-6.
18. Fan WC, Ting WY, Lee MC, et al. Latent TB infection in newly diagnosed lung cancer patients - A multicenter prospective observational study. *Lung Cancer* 2014;85:472-8.